Cellectar Biosciences, Inc.: 10-Q filed 2017-11-09

Name: Cellectar Biosciences, Inc.: 10-Q filed 2017-11-09
Creator: Cellectar Biosciences, Inc.

What Cellectar Biosciences, Inc. reported in its quarterly report filed 2017-11-09 (fiscal Q3 2017): 26 published measures, 66 facts as tagged in accession 0001144204-17-057737.

This filing

Form: 10-Q (quarterly report)
Filed: 2017-11-09
Fiscal period: fiscal Q3 2017
Accession: 0001144204-17-057737 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cellectar Biosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-09-30	9,871,367	USD
At 2016-12-31	15,324,580	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-09-30	2,278,703	USD
At 2016-12-31	1,784,708	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2017-09-30	7,592,664	USD
At 2016-12-31	13,539,872	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2017-09-30	5,662,227	USD
At 2016-12-31	11,444,619	USD
At 2016-09-30	5,645,968	USD
At 2015-12-31	3,857,791	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-3,470,699	USD	92
2017-01-01 to 2017-09-30	-9,483,551	USD	273
2016-07-01 to 2016-09-30	-2,286,860	USD	92
2016-01-01 to 2016-09-30	-3,595,200	USD	274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	-8,194,234	USD	273
2016-01-01 to 2016-09-30	-5,933,450	USD	274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	346,703	USD	273
2016-01-01 to 2016-09-30	5,258	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	2,758,545	USD	273
2016-01-01 to 2016-09-30	7,726,885	USD	274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	-346,703	USD	273
2016-01-01 to 2016-09-30	-5,258	USD	274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-09-30	-80,270,577	USD
At 2016-12-31	-70,787,026	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2017-09-30	1,496,566	USD
At 2016-12-31	1,444,058	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	176,324	USD	92
2017-01-01 to 2017-09-30	573,084	USD	273
2016-07-01 to 2016-09-30	174,246	USD	92
2016-01-01 to 2016-09-30	397,132	USD	274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-3,483,768	USD	92
2017-01-01 to 2017-09-30	-9,512,473	USD	273
2016-07-01 to 2016-09-30	-2,467,888	USD	92
2016-01-01 to 2016-09-30	-6,801,507	USD	274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-09-30	6,687,467	USD
At 2016-12-31	12,193,188	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-09-30	2,132,660	USD
At 2016-12-31	1,632,876	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2017-09-30	1,675,462	USD
At 2016-12-31	1,675,462	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	2,333,058	USD	92
2017-01-01 to 2017-09-30	6,365,868	USD	273
2016-07-01 to 2016-09-30	1,305,610	USD	92
2016-01-01 to 2016-09-30	3,310,248	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-09-30	13,477,170	shares
At 2016-12-31	10,368,325	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2017-09-30	87,863,106	USD
At 2016-12-31	83,451,222	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2017-09-30	11,872	USD
At 2016-12-31	11,872	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2017-09-30	970,240	USD
At 2016-12-31	693,569	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	1,150,710	USD	92
2017-01-01 to 2017-09-30	3,146,605	USD	273
2016-07-01 to 2016-09-30	1,162,278	USD	92
2016-01-01 to 2016-09-30	3,491,259	USD	274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	294,195	USD	273
2016-01-01 to 2016-09-30	269,317	USD	274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	13,069	USD	92
2017-01-01 to 2017-09-30	28,922	USD	273
2016-07-01 to 2016-09-30	181,028	USD	92
2016-01-01 to 2016-09-30	3,206,307	USD	274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	364	USD	273
2016-01-01 to 2016-09-30	3,702	USD	274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	0	USD	273
2016-01-01 to 2016-09-30	7,371,121	USD	274

Inspect the source

Entity: Cellectar Biosciences, Inc. / CIK 0001279704
Captured: 2026-09-20T07:48:31.991Z
SEC response SHA-256: 44da00fed89c835867d9290b98319109f07ad849957763fd081353f99891a212

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001279704.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))